HLF Earnings

HLF reported its earnings on 2026-02-18, showcasing a revenue of 1.28B against an estimate of 1.50B, resulting in a -14.47% surprise. The EPS was 0.45, surpassing the expected 0.47 by -4.26%. The stock experienced a 18.32% price change on the earnings day and a 18.5% change over the next five days, reflecting market reactions to the results.

Following HLF's earnings announcement on 2026-02-18, the stock price moved by 18.32% on the day of the release. Over the subsequent five days, it saw a 18.5% change. Historically, HLF's stock price tends to shift by an average of 1.88% in the 10 days leading up to earnings and 6.11% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate HLF's annual revenue to reach 1.26B, while the EPS is projected at 0.67. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between HLF's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, HLF's stock price typically moves by 1.88% in the 10 days before its earnings and 6.11% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 0.67 and revenue of 1.26B.

The earnings report shows strong performance in key areas like Adjusted EBITDA, operating cash flow, and debt reduction. Despite some challenges like FX headwinds and regional sales declines in China, the company has demonstrated financial discipline and strategic growth initiatives. The Q&A highlights optimism in future growth, particularly in India, and strategic focus on personalized nutrition. However, lack of detailed guidance for China and minimal contribution from Pro2col slightly temper the outlook. Overall, the positive financial metrics and strategic initiatives are expected to boost the stock price in the short term.